Institutional members access full text with Ovid®

Share this article on:

The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey

Ganz, Michael L. MS, PhD; Sugarman, Rebecca MSc; Wang, Rosa MHA; Hansen, Brian Bekker MSc; Håkan-Bloch, Jonas MSc

doi: 10.1097/MIB.0000000000000742
Original Article

Background: Approximately 593,000 to 780,000 people in the United States (US) have been diagnosed with Crohn's disease (CD), and an additional 33,000 are diagnosed yearly. Our objective was to estimate CD's impact on medical costs, lost earnings, work and school absences, health status, and health-related quality of life (HRQOL) in the US and to compute current and forecasted national costs.

Methods: We used the nationally representative Medical Expenditure Panel Survey to match 539 respondents with CD to similar respondents without any inflammatory bowel disease (IBD). We estimated annual costs, work and school absences, and self-assessed health status. HRQOL was assessed by the SF-12 Physical Component Summary and Mental Component Summary (PCS and MCS) scores. CD prevalence rates, population counts, and costs were used to forecast total national costs.

Results: CD is associated with higher medical costs ($13,446 versus $6029) and lost earnings ($1249 versus $644) and is responsible for $3.48 billion in total national costs (expected to increase to $3.72 billion in 2025). Respondents with CD were more likely to miss work (38% versus 33%) or school (64% versus 33%), less likely to report being in excellent or very good physical health (24% versus 63%), and experienced lower HRQOL measured by the Physical Component Summary (43.4 versus 48.5) and Mental Component Summary (48.6 versus 50.0) than those without IBD.

Conclusions: CD is responsible for increased medical care costs and lower earnings, health status, and HRQOL. These data can serve as benchmarks when examining future CD-related costs and HRQOL.

Supplemental Digital Content is Available in the Text.Article first published online 14 March 2016.

*Evidera, Lexington, Massachusetts; and

Novo Nordisk A/S, Global Market Access, Søborg, Denmark.

Reprints: Michael L. Ganz, MS, PhD, Evidera, 430 Bedford Street, Suite 300, Lexington, MA 02420 (e-mail:

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

This study was funded by Novo Nordisk A/S, Denmark. M. L. Ganz, R. Sugarman, and R. Wang are employees of Evidera, a consulting organization that received funding from Novo Nordisk A/S to conduct this study, and were so at the time this research was conducted. B. B. Hansen and J. Håkan-Bloch are employees of Novo Nordisk A/S and were so at the time this study was conducted. B. B. Hansen is a Novo Nordisk A/S shareholder. The authors have no other relevant affiliations or financial relationships to declare apart from those disclosed.

Received November 3, 2015

Accepted November 16, 2015

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website